Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BCAX
BCAX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BCAX News
Bicara Therapeutics Reports Q4 2025 Financial Results
1d ago
seekingalpha
BICARA THERAPEUTICS INC Reports Q4 Net Loss of $37.4 Million; FY2025 Net Loss Totals $138.0 Million
1d ago
moomoo
BICARA THERAPEUTICS BEGINS PHASE 3 OF FORTIFI-HN01 KEY TRIAL; INTERIM RESULTS ANTICIPATED BY MID-2027
1d ago
moomoo
Bicara Therapeutics Advances Ficerafusp Alfa in Clinical Trials
1d ago
Newsfilter
Bicara Therapeutics CEO Sells Stock Options
22h ago
Fool
Bicara Therapeutics CEO Sells Shares Amid Strong Stock Performance
22h ago
NASDAQ.COM
Key Stock Market Movers: Nvidia, Eli Lilly, Alcoa, Coinbase, and Strategic Developments
1d ago
Barron's
Bicara CEO Sells Shares Under 10b5-1 Plan
4d ago
Fool
Bicara Therapeutics CEO Sells Shares Amid Strategic Developments
4d ago
NASDAQ.COM
Bicara Therapeutics Grants Stock Options to New Employee
Mar 04 2026
Newsfilter
Bicara Therapeutics Announces Public Offering Details
Feb 25 2026
seekingalpha
Bicara Therapeutics Prices Public Offering at $16.00 per Share
Feb 25 2026
Newsfilter
Bicara Therapeutics Launches $150M Public Offering
Feb 24 2026
seekingalpha
Bicara Therapeutics Presents New Data on Ficerafusp Alfa Therapy
Feb 19 2026
Newsfilter
Bicara Therapeutics Reports Efficacy Data for 750mg Dose of Ficerafusp Alfa
Dec 06 2025
Globenewswire
Bicara Therapeutics Reports 57% Response Rate for 750mg Ficerafusp Alfa in HNSCC Study
Dec 06 2025
Newsfilter
Show More News
